GSK Kicks Off M&A Push As Deal Speculation And Sunny Skies Set The Scene For J.P. Morgan

GSK will pay up to $1.15bn for IDRx, Lilly is said to be making a play for Scorpion, Biogen offered to buy Sage and Gilead announced a partnership with Leo Pharma ahead of the J.P. Morgan Healthcare Conference.

Rumored deals and some confirmed transactions garnered attention in the lead-up to J.P. Morgan (Shutterstock)

Merger and acquisition news materialized in the days leading up to the J.P. Morgan Healthcare Conference, kicking off in San Francisco on 13 January, but deal watchers still were waiting for some deals to be finalized in the final hours before the annual meeting. GSK was the first out of the gate, late at night on the West Coast on 12 January, with its plan to buy IDRx for up to $1.15bn.

More from J.P. Morgan

More from R&D